LLY
Eli Lilly and Company
Pharmaceutical company focused on oncology, immunology, neuroscience. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
0
$0
Total Volume
$0
57 transactions
Net Activity
+$0
Net buying
Sentiment Rating
Neutral / BalancedCEO Conviction Index
No Recent Signal
Key Drivers
- •Balanced trading volume with net neutral buying and selling activity.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
LLY has an insider buy conviction of 50%, compared to the Pharmaceuticals sector buy average of 50%. LLY ranks #2 in insider activity out of 2 tracked companies in its industry.
Multiple Insiders
S - Sale Insiders
$0 total
Over the last 90 days, corporate insiders at Eli Lilly and Company (LLY) engaged in a total of 57 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 0 were sales. The total volume of insider trading reached $0.
The net insider activity for LLY shows a net buying bias of $0. This activity represents a 50% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (S - Sale Insiders), who traded 54.8K shares valued at $0 on Aug 17, 2026.
Quick Actions
Explore Peers in Drug Manufacturers
Compare insider activity and sentiment scores across similar organizations.
Related News & Analyst Reports
Read original insights and educational research covering Eli Lilly and Company and the Drug Manufacturers sector.
The AI Circular Valuation Bubble: Inside the Venture-Cloud Loop
An in-depth investigation into how technology giants and AI startups engage in circular capital flows, investing venture capital in exchange for cloud services and hardware, creating a closed-loop economy that artificially inflates valuations.
Sequoia Capital and the Mechanics of Venture Lock-Up Extensions
Sequoia Capital pioneered the use of voluntary lock-up extensions to signal portfolio company confidence. This report analyzes the market-price impact of Sequoia extension announcements and whether they have historically justified the delay.
The Role of Insider Trading in M&A: Deciphering the Pre-Merger Signals
M&A deals are the most fertile ground for illegal insider trading, and for legal cluster buys that signal a company is strategically attractive. This guide separates the legal signal from the illegal noise in M&A-adjacent Form 4 activity.
Venture-Backed Biotech IPOs: Inside the 2026 Buying Spree
2026 saw a resurgence of venture-backed biotech IPOs, accompanied by unusually high post-lockup insider buying. This report documents the specific Form 4 cluster events, purchase sizes, and 90-day price performance across a dozen recent biotech offerings.
Biotech Insider Buying: Analyzing Clinical Trial Catalysts
Biotech insiders walk a legal tightrope near trial readouts. This report identifies statistically significant buying clusters at small-cap biotechs 30-90 days before Phase 2 and Phase 3 data announcements.
Deciphering Option Exercises (Code M) vs. Open Market Purchases (Code P)
Transaction code M (option exercise) is often mistaken for bullish conviction, but it usually means nothing. Learn why Code P open-market purchases are the only Form 4 entries that signal genuine insider belief.
FAQs About Eli Lilly and Company Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for LLY.